Show simple item record

dc.creatorMijušković, Mirjana
dc.creatorStanojević, Ivan
dc.creatorMilović, Novak
dc.creatorCerović, Snežana
dc.creatorPetrović, Dejan
dc.creatorMaksić, Đoko
dc.creatorKovacević, Božidar
dc.creatorAnđelić, Tamara
dc.creatorAleksić, Predrag
dc.creatorTerzić, Brankica
dc.creatorĐukić, Mirjana
dc.creatorVojvodić, Danilo
dc.date.accessioned2019-09-02T12:08:12Z
dc.date.available2019-09-02T12:08:12Z
dc.date.issued2018
dc.identifier.issn0301-1623
dc.identifier.urihttp://farfar.pharmacy.bg.ac.rs/handle/123456789/3231
dc.description.abstractThe objective of this prospective follow-up trial was to ascertain whether the urinary kidney injury molecule-1 (uKIM-1) associates with tumor tissue (tKIM-1) expression and with the pathological characteristics of clear renal cell carcinoma (cRCC) in radically nephrectomized (RN) and/or in partially nephrectomized (PN) patients with cRCC, pre- and postoperatively. This clinical study included 40 patients subjected to RN/PN (cRCC group) and 30 healthy volunteers (control group). Urinary KIM-1 was determined by ELISA TIM-1/KIM-1 kit and normalized by urinary creatinine. Immunohistochemical staining (monoclonal anti-human anti-TIM-1/KIM-1/HAVCR antibody) was used for semiquantitative analysis of the tKIM-1 expression and expressed as a score (% KIM-1 positively stained tubules). Both markers were interpreted in terms of the tumor characteristics comprising tumor size, Fuhrman grade, pathological (pT) stage, tumor/nodes/metastasis (TNM) stage, lymphovascular invasion and type of surgery RN/PN. Preoperative uKIM-1 was significantly higher in the cRCC group compared to controls, such as uKIM-1 was statistically higher in RN than in PN patients. Postoperatively, uKIM-1 decreased to control values. Expression of tKIM-1 was documented in all nephrectomized patients. Significant associations were achieved between uKIM-1 and tKIM-1 and with considered tumor characteristics, especially with tumor size and grade. Based on the accomplished associations, we found uKIM-1 as a highly sensitive marker for cRCC diagnosis. The clinical trial registration number: 1110-2012.en
dc.publisherSpringer, Dordrecht
dc.relationMinistry of Defense of the Republic of Serbia (Project no. MFVMA/3/13-15)
dc.rightsrestrictedAccess
dc.sourceInternational Urology and Nephrology
dc.subjectDisease markersen
dc.subjectKIM-1en
dc.subjectKidneyen
dc.subjectNephrectomyen
dc.subjectClear renal cell carcinomaen
dc.subjectTumorsen
dc.titleTissue and urinary KIM-1 relate to tumor characteristics in patients with clear renal cell carcinomaen
dc.typearticle
dc.rights.licenseARR
dcterms.abstractСтанојевић, Иван; Церовић, Снежана; Максић, Ђоко; Ковацевић, Божидар; Aлексић, Предраг; Aнђелић, Тамара; Терзић, Бранкица; Војводић, Данило; Петровић, Дејан; Ђукић, Мирјана; Миловић, Новак; Мијушковић, Мирјана;
dc.citation.volume50
dc.citation.issue1
dc.citation.spage63
dc.citation.epage70
dc.citation.other50(1): 63-70
dc.citation.rankM23
dc.identifier.wos000419704800010
dc.identifier.doi10.1007/s11255-017-1724-6
dc.identifier.pmid29052086
dc.identifier.scopus2-s2.0-85031827150
dc.identifier.rcubconv_4033
dc.type.versionpublishedVersion


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record